Omar Castaneda Puglianini, MD
Medical Oncology · Tampa, FLNPI 1487927299
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,002 of the $61,787 with a category attached, or 63.1%. 10 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 39.3% of the total.
Across 66 payments — averaging $936.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$24K
- Johnson & Johnson$24K
- Adaptive Biotechnologies Corporation$5K
- Legend Biotech USA Inc.$4K
- Bristol Myers Squibb$2K
- Janssen Scientific Affairs, LLC$2K
- plus $304 from 4 others
Across 10 payments — averaging $623.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$5K
- GSK$1K
What the payments were for
- Consulting fees$12,68821%
- Speaking & faculty fees$39,00263%
- Travel & lodging$8,17513%
- Food & beverage$1,9223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 16 | $24,258 |
| Johnson & Johnson(2 entities) | 28 | $23,553 |
| Adaptive Biotechnologies Corporation | 4 | $4,500 |
| Legend Biotech USA Inc. | 6 | $4,305 |
| Bristol Myers Squibb | 5 | $2,468 |
| Janssen Scientific Affairs, LLC | 2 | $2,399 |
| Sanofi | 1 | $121 |
| Gilead | 2 | $93 |
| Beigene USA, Inc. | 1 | $69 |
| Medtronic | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,787 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 11 | $309,038 |
| Atovaquone | 22 | $12,655 |
| Acyclovir | 119 | $1,646 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 51 | $235 |
| Oxycodone Hcl | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.